New Orleans
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
111- Orthopaedic Surgery
- 111
Supplier vetting for orthopedic accounts
An orthopedic practice or surgery center typically asks a new biologics vendor for the same baseline documentation regardless of region: how donors were screened, how quickly tissue was processed after recovery, and what sterility testing was completed on the specific lot before release. A surgery center with a value analysis committee often formalizes this into a standing document request.
Precision Biologics ties documentation to the lot rather than the product line, so a practice evaluating a purchase can request a certificate of analysis, donor eligibility summary, and lot release record before committing to an order.
NPI-based account verification
New accounts are verified against an NPI number through the NPPES registry before activation. For a surgery center with several credentialed surgeons, this creates a clear, individually attributable ordering record rather than a shared general account.
Logistics for shipments into the Gulf South
Cryopreserved Wharton's jelly products are packed on dry ice in validated containers for overnight delivery and require storage at -80 degrees C once received; a practice should have a receiving step that checks container temperature and records the lot number on arrival. Shelf-stable formats, including the lyophilized Wharton's jelly product and the lyophilized exosome products, do not need that cold-chain step, which can simplify logistics for a practice managing a mixed order.
Regulatory review and account onboarding
Whether a specific intended use of a Wharton's jelly allograft meets the minimal-manipulation and homologous-use standard in 21 CFR 1271.10 is a determination the ordering practice and its counsel make; Precision Biologics does not make that determination on a clinic's behalf. Exosome products carry no FDA approval and are generally regulated as biologic drugs, so purchasing and use decisions for those products rest with the ordering physician and their regulatory counsel. A practice should separately confirm its physicians' standing with the Louisiana medical board as part of its own compliance review.
Account setup includes an NPI verification step and access to physician-level documentation calls that walk through certificates of analysis and lot records.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
How quickly can a new account place its first order after verification?+
Once an NPI number is verified, the account can review available documentation and place an order. Exact timelines depend on the practice's internal purchasing process.
Can our surgery center request documentation before we add a product to our formulary?+
Yes. Verified accounts can request a certificate of analysis, donor eligibility summary, and lot release record for any lot under consideration.
Will Precision Biologics tell us whether a use case qualifies under 21 CFR 1271.10?+
No. That determination belongs to the ordering practice and its own regulatory counsel. Precision Biologics provides lot-level documentation to support that review.